Im Folgenden finden Sie eine durchsuchbare und filterbare Liste unserer Nachrichten, Pressemitteilungen, Whitepaper, Artikel, wissenschaftlichen Poster und vieles mehr.
Wenn Sie etwas nicht finden können, lassen Sie es uns bitte wissen, und wir werden uns so schnell wie möglich mit Ihnen in Verbindung setzen.
Molecular tumor board for gynecologic malignancies: the real-world experience from the Department for Gynecology and Gynecologic Oncology of Kliniken Essen-Mitte
Tsibulak, Irina et al. International Journal of Gynecological Cancer, Volume 0, Issue 0, 100054. https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(24)04617-6/fulltextQuelle öffnenDetermination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach
Cancer Res Clin Oncol 150, 367 (2024). https://doi.org/10.1007/s00432-024-05901-4Quelle öffnenA multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
Schell, MJ. Nat Commun. 2016;7:11743Quelle öffnenBioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
Malgerud, L. et al. Mol Oncol. 2017;11(10):1413-1429Quelle öffnenConsolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
Hirotsu, Y. et al. Int J Mol Sci. 2020;21(11):3895Quelle öffnenWhole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study
Jaeger, BAS. Geburtshilfe Frauenheilkd. 2023;83(9):1138-1147Quelle öffnenRewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
Jackson, D.B. et al. Pharmaceutics 2023, 15(6), 1673Quelle öffnenDetermination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
Mustea, A. et al. Cancers 2023, 15(7), 2023Quelle öffnenWhole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
Brock, S. et al. Front. Mol. Med. 2022, 2:1035290. https://doi.org/10.3389/fmmed.2022.1035290Quelle öffnenAdvancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
Soldatos, T. G. et al. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):540-555. doi: 10.1002/psp4.12765Quelle öffnenEvaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
Heydt, C. et al. J. Mol. Pathol. 2022, 3(1), 53-67; https://doi.org/10.3390/jmp3010006Quelle öffnenApplication of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
Kim, S. et al. Clin Transl Sci. 2022 Jun;15(6):1430-1438. doi: 10.1111/cts.13254Quelle öffnenThe COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
Brock, S. et al. Front. Mol. Med. 2022, 2:1035215. https://doi.org/10.3389/fmmed.2022.1035215Quelle öffnenTarget adverse event profiles for predictive safety in the postmarket setting
Peter Schotland, Rebecca Racz, David B. Jackson, Theodoros G. Soldatos, Robert Levin, David G. Strauss and Keith Burkhart. Clinical Pharmacology & Therapeutics Volume 109, Issue 5, Pages: 1159-1362 (May 2021)Quelle öffnenA case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development
Kim, S. et al. Clin Transl Sci . 2022 Apr;15(4):1003-1013. doi: 10.1111/cts.13219Quelle öffnen